sleep apnea, Food and Drug Administration

FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
Elli Lilly’s weight loss drug to be covered in Medicare insurance in US for THIS treatment - all you need to know
Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly medication. This comes after Zepbound’s FDA approval for a secondary use, allowing Medicare coverage.
FDA approves first ever medication for obstructive sleep apnea — here's what that means
The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to find out more information.
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated that almost 50 million adults in employer plans meet the clinical criteria for taking such drugs, which can cost thousands of dollars annually per person," according to a report from Kaiser Family Health (KFF) in October.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Zepbound can now be covered by Medicare
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly expand access to the popular, yet costly treatment.
HealthDay on MSN11h
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
HealthDay on MSN13d
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health ...
The National on MSN4h
Two years on, are GLP-1 drugs such as Ozempic and Mounjaro here to stay?
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...
Becker's Hospital Review13h
GLP-1s cut surgery complication risk in some patients: Study
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs ...
HealthDay on MSN1d
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...